131 related articles for article (PubMed ID: 38350360)
21. Discovery of quinazoline HPK1 inhibitors with high cellular potency.
Toure M; Johnson T; Li B; Schmidt R; Ma H; Neagu C; Lopez AU; Wang Y; Guler S; Xiao Y; Henkes R; Ho K; Zhang S; Chu CL; Gundra UM; Porichis F; Li L; Maurer CK; Fang Z; Musil D; DiPoto M; Friis E; Jones R; Jones C; Cummings J; Chekler E; Tanzer EM; Huck B; Sherer B
Bioorg Med Chem; 2023 Sep; 92():117423. PubMed ID: 37531921
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening.
Ge H; Peng L; Sun Z; Liu H; Shen Y; Yao X
Front Pharmacol; 2022; 13():850855. PubMed ID: 35370676
[TBL] [Abstract][Full Text] [Related]
23. Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors.
Xie C; Liu B; Song Z; Yang Y; Dai M; Gao Y; Yao Y; Ding C; Ai J; Zhang A
J Med Chem; 2023 Dec; 66(23):16201-16221. PubMed ID: 37990878
[TBL] [Abstract][Full Text] [Related]
24. Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling.
Ling P; Meyer CF; Redmond LP; Shui JW; Davis B; Rich RR; Hu MC; Wange RL; Tan TH
J Biol Chem; 2001 Jun; 276(22):18908-14. PubMed ID: 11279207
[TBL] [Abstract][Full Text] [Related]
25. Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation.
Feng D; Liu B; Chen Z; Xu J; Geng M; Duan W; Ai J; Zhang H
J Biomol Struct Dyn; 2024 Jan; ():1-13. PubMed ID: 38198294
[TBL] [Abstract][Full Text] [Related]
26. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Yang L; Zhao Q; Chen T; Liu W; Qiu X; Chen J; Huang S; Huang R; Dong L
Clin Exp Med; 2023 Nov; 23(7):3767-3780. PubMed ID: 37106265
[TBL] [Abstract][Full Text] [Related]
27. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress.
Chen H; Guan X; He C; Lu T; Lin X; Liao X
Expert Opin Ther Targets; 2024 Apr; 28(4):237-250. PubMed ID: 38650383
[TBL] [Abstract][Full Text] [Related]
28. Protein phosphatase 4 is a positive regulator of hematopoietic progenitor kinase 1.
Zhou G; Boomer JS; Tan TH
J Biol Chem; 2004 Nov; 279(47):49551-61. PubMed ID: 15364934
[TBL] [Abstract][Full Text] [Related]
29. HPK1 Influences Regulatory T Cell Functions.
Sawasdikosol S; Zha R; Fisher TS; Alzabin S; Burakoff SJ
Immunohorizons; 2020 Jul; 4(7):382-391. PubMed ID: 32631900
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1.
Degnan AP; Kumi GK; Allard CW; Araujo EV; Johnson WL; Zimmermann K; Pearce BC; Sheriff S; Futran A; Li X; Locke GA; You D; Morrison J; Parrish KE; Stromko C; Murtaza A; Liu J; Johnson BM; Vite GD; Wittman MD
ACS Med Chem Lett; 2021 Mar; 12(3):443-450. PubMed ID: 33732413
[TBL] [Abstract][Full Text] [Related]
31. Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling.
Zeng S; Jin Y; Xia H; Shang Y; Li Y; Wang Z; Huang W
Bioorg Chem; 2024 Feb; 143():107016. PubMed ID: 38086239
[TBL] [Abstract][Full Text] [Related]
32. The development of small-molecule inhibitors targeting HPK1.
Zhou L; Wang T; Zhang K; Zhang X; Jiang S
Eur J Med Chem; 2022 Dec; 244():114819. PubMed ID: 36209628
[TBL] [Abstract][Full Text] [Related]
33. Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase.
Ling P; Yao Z; Meyer CF; Wang XS; Oehrl W; Feller SM; Tan TH
Mol Cell Biol; 1999 Feb; 19(2):1359-68. PubMed ID: 9891069
[TBL] [Abstract][Full Text] [Related]
34. Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes.
Ma W; Xia C; Ling P; Qiu M; Luo Y; Tan TH; Liu M
Oncogene; 2001 Mar; 20(14):1703-14. PubMed ID: 11313918
[TBL] [Abstract][Full Text] [Related]
35. Activation or suppression of NFkappaB by HPK1 determines sensitivity to activation-induced cell death.
Brenner D; Golks A; Kiefer F; Krammer PH; Arnold R
EMBO J; 2005 Dec; 24(24):4279-90. PubMed ID: 16341093
[TBL] [Abstract][Full Text] [Related]
36. Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway.
Sawasdikosol S; Pyarajan S; Alzabin S; Matejovic G; Burakoff SJ
J Biol Chem; 2007 Nov; 282(48):34693-9. PubMed ID: 17895239
[TBL] [Abstract][Full Text] [Related]
37. Theoretical Studies on Selectivity of HPK1/JAK1 Inhibitors by Molecular Dynamics Simulations and Free Energy Calculations.
Ge H; Tang C; Pan Y; Yao X
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768974
[TBL] [Abstract][Full Text] [Related]
38. Interaction of hematopoietic progenitor kinase 1 and c-Abl tyrosine kinase in response to genotoxic stress.
Ito Y; Pandey P; Sathyanarayana P; Ling P; Rana A; Weichselbaum R; Tan TH; Kufe D; Kharbanda S
J Biol Chem; 2001 May; 276(21):18130-8. PubMed ID: 11278340
[TBL] [Abstract][Full Text] [Related]
39. Identification of Potent Reverse Indazole Inhibitors for HPK1.
Yu EC; Methot JL; Fradera X; Lesburg CA; Lacey BM; Siliphaivanh P; Liu P; Smith DM; Xu Z; Piesvaux JA; Kawamura S; Xu H; Miller JR; Bittinger M; Pasternak A
ACS Med Chem Lett; 2021 Mar; 12(3):459-466. PubMed ID: 33738073
[TBL] [Abstract][Full Text] [Related]
40. Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1.
Arnold R; Patzak IM; Neuhaus B; Vancauwenbergh S; Veillette A; Van Lint J; Kiefer F
Mol Cell Biol; 2005 Mar; 25(6):2364-83. PubMed ID: 15743830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
